---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-036697"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T21:49:05.740699+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sangamo reports updated Phase 1/2 Alta data for hemophilia A gene therapy; FVIII maintained through ~4 years

## Summary
- Single infusion of giroctocogene fitelparvovec (3e13 vg/kg) maintains FVIII activity in mild-to-normal range through up to 208 weeks.
- Mean annualized bleeding rate in high-dose cohort was 0 in year 1 and 1.2 overall; no participants resumed prophylaxis.
- No confirmed FVIII inhibitor development, no thrombotic events, and liver safety resolved without sequelae.
- Pfizer expects pivotal Phase 3 AFFINE trial readout in mid-2024.
- Updated data to be presented at ASH Annual Meeting on December 11, 2023.

## SEC filing metadata
- accession: 0001628280-23-036697
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828023036697/0001628280-23-036697-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828023036697/sgmo-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-036697
- JSON: https://secwatch.observer/filing/0001628280-23-036697.json
- Plain text: https://secwatch.observer/filing/0001628280-23-036697.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.